Stay in the know
Receive timely insights and briefings from HSF Kramer, tailored to keep you informed and ahead
Subscribe now
Herbert Smith Freehills Kramer (HSF Kramer) is pleased to be advising CSL on its recently announced proposed demerger of its Seqirus business (Seqirus) as a standalone ASX-listed entity by the end of Financial Year 2026.
Seqirus is one of the world’s largest influenza vaccine providers, dedicated to advancing public health through innovative vaccine solutions and pandemic preparedness.
The HSF Kramer team is led by partners Priscilla Bryans, Baden Furphy, Alexander Mackinnon, and Michael Ziegelaar, with partner Ryan Leslie advising on the tax aspects of the transaction.
Key contacts
Priscilla Bryans
Partner, Melbourne
Baden Furphy
Partner, Melbourne
Alexander Mackinnon
Partner, Melbourne
Michael Ziegelaar
Partner, Melbourne
Ryan Leslie
Partner, Melbourne
Media contact
For further information on this news article, please contact:
Gina Baldassarre
External Communications Manager
Sydney
More news
17 August 2026
Herbert Smith Freehills Kramer welcomes expert infrastructure partner Marcus Davenport to the firm
Leading international law firm, Herbert Smith Freehills Kramer (HSF Kramer) welcomes Marcus Davenport to its growing projects, energy and infrastructure …
13 August 2026
Strategies and liquidity options evolve as billion-dollar deals rise in Australian private M&A – HSF Kramer Report
The return of the billion-dollar deal was the defining feature of the last year in private dealmaking, with a new report from HSF Kramer finding the …
12 August 2026
Herbert Smith Freehills Kramer advises Squadron Energy on $2.7 billion renewable energy portfolio project financing
We advised Squadron Energy on the refinancing of its $2.7 billion renewable energy asset portfolio in Australia.